Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1), appears to have no interactions with the immunosuppressive therapies and to have also cardio-protective effects in patients with known atherosclerotic disease or heart failure, making it an interesting option in these high risk patients. The gene discussed is GCG; the disease is heart failure.